

2019

Diaryl hydroxylamines as pan or dual inhibitors of indoleamine 2,3-dioxygenase-1, indoleamine 2,3-dioxygenase-2 and tryptophan dioxygenase

Maria Winters

James B. DuHadaway

Khoa N. Pham

Ariel Lewis-Ballester

Shorouk Badir

See next page for additional authors

[Let us know how access to this document benefits you.](#)

Follow this and additional works at: https://repository.brynmawr.edu/physics_pubs

 Part of the [Physics Commons](#)

Custom Citation

Winters, Maria, James B. DuHadaway, Khoa N. Pham, Ariel Lewis-Ballester, Shorouk Badir, Jenny Wai, Eesha Sheikh, Syun-Ru Yeh, George C. Prendergast, Alexander J. Muller, William P. Malachowski. 2019. "Diaryl Hydroxylamines as Pan or Dual Inhibitors of Indoleamine 2,3-Dioxygenase-1, Indoleamine 2,3-Dioxygenase-2 and Tryptophan Dioxygenase." *European Journal of Medicinal Chemistry* 162: 455-464.

This paper is posted at Scholarship, Research, and Creative Work at Bryn Mawr College. https://repository.brynmawr.edu/physics_pubs/141

For more information, please contact repository@brynmawr.edu.

Authors

Maria Winters, James B. DuHadaway, Khoa N. Pham, Ariel Lewis-Ballester, Shorouk Badir, Jenny Wai, Eesha Sheikh, Syun-Ru Yeh, George C. Pendergast, Alexander J. Muller, and William Paul Malachowski

Diaryl Hydroxylamines as Pan or Dual Inhibitors of Indoleamine 2,3-Dioxygenase-1, Indoleamine 2,3- Dioxygenase-2 and Tryptophan Dioxygenase

*Maria Winters¹, James B. DuHadaway², Khoa N. Pham⁵, Ariel Lewis-Ballester⁵, Shorouk Badir¹,
Jenny Wai¹, Eesha Sheikh¹, Syun-Ru Yeh⁵, George C. Prendergast^{2,3,4}, Alexander J. Muller^{2,4},
William P. Malachowski¹**


¹Department of Chemistry, Bryn Mawr College, Bryn Mawr, Pennsylvania 19010,
USA. ²Lankenau Institute for Medical Research, Wynnewood, Pennsylvania 19096,
USA. ³Department of Pathology, Anatomy & Cell Biology and ⁴Kimmel Cancer Center, Thomas
Jefferson University, Philadelphia, Pennsylvania 19104, USA. ⁵Department of Physiology and
Biophysics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York
10461, United States

William P. Malachowski, email: wmalacho@brynmawr.edu; Alexander J. Muller, e-mail:
muller@limr.org.

Address correspondence regarding the chemistry to William P. Malachowski at the Department of
Chemistry, Bryn Mawr College, 101 N. Merion Ave., Bryn Mawr, PA 19010-2899; phone: 610-
526-5016; fax: 610-526-5086; e-mail: wmalacho@brynmawr.edu. Address correspondence
regarding the biology to Alexander J. Muller or George C. Prendergast at Lankenau Institute for

Medical Research, 100 Lancaster Ave, Wynnewood, PA 19096, Wynnewood, PA 19096; phone: 610-645-8034; fax: 610-645-2095; e-mail: muller@limr.org or prendergast@limr.org, respectively.

GRAPHICAL ABSTRACT



HIGHLIGHTS

- Extension of mono to diaryl hydroxylamines illuminates activities as potent pan and dual inhibitors of IDO1, IDO2 and TDO.
- There is a paucity of previous reports of dual and pan inhibitors for these enzymes, which regulate the kynurenine pathway.
- Aryl halide substitution generated the most potent derivatives studied.

ABSTRACT Tryptophan (Trp) catabolizing enzymes play an important and complex role in the development of cancer. Significant evidence implicates them in a range of inflammatory and immunosuppressive activities. Whereas inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1) have been reported and analyzed in the clinic, fewer inhibitors have been described for

tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase-2 (IDO2) which also have been implicated more recently in cancer, inflammation and immune control. Consequently the development of dual or pan inhibitors of these Trp catabolizing enzymes may represent a therapeutically important area of research. This is the first report to describe the development of dual and pan inhibitors of IDO1, TDO and IDO2.

1. Introduction

In mammals and other vertebrates, three enzymes, IDO1, IDO2 and TDO, catalyze the rate-limiting first step of tryptophan catabolism down the kynurenine pathway which accounts for $\geq 95\%$ of tryptophan catabolism^{1,2}. Whereas TDO is a predominantly hepatic enzyme functioning to maintain tryptophan homeostasis, IDO1 is induced by inflammation, particularly by IFN γ , and can be found in lymphoid tissues and organs, along mucosal surfaces, and in the placenta and epididymis³. IDO2 has been less thoroughly investigated than the other two enzymes, but the available data indicate it has a more restricted expression than IDO1³. In cancer patients, IDO1 expression has been observed at varying levels and frequencies in most tumor types while TDO is strongly expressed in hepatocarcinoma, but also weakly in many other tumor types³. Extensive preclinical evidence indicates that IDO1 inhibitors can relieve T cell suppression and enhance cancer therapeutic responses^{4,5}, including when combined with cytotoxic chemotherapy, radiotherapy or immune checkpoint therapy⁶⁻⁹. Nevertheless, the failure of the IDO1-selective inhibitor epacadostat to provide a benefit in combination with the immune checkpoint agent pembrolizumab in a recent phase III clinical trial¹⁰ in melanoma patients highlights the continuing challenges to exploit the role IDO1 has in regulating the immune system.

While this trial has raised many questions¹¹, attendant with its failure has been the growing recognition of the complex role and importance of the related dioxygenases, TDO and IDO2^{4, 5}, which, like IDO1, also exert root functions in cancer inflammatory programming. It has become clear that IDO1 drives both neovascularization along with immunosuppression in tumors.^{12, 13} TDO promotes immunosuppression, but also other processes that promote metastatic progression^{3, 14-17}. IDO2 drives inflammation in autoimmune and cancer settings including pancreas cancer¹⁸⁻²⁰. Combo or pan IDO1/TDO/IDO2 inhibitors will potentially offer metabolic adjuvants to illuminate key questions concerning the peculiar nature of chronic inflammatory states that sustain cancer²¹. As metabolic adjuvants, IDO1-selective inhibitors do not plumb the full potential of blunting Trp catabolism. Emerging evidence indicates that TDO and IDO2 are jointly activated with IDO1 in many tumors^{3, 14-17, 22}, arguing for independent as well as overlapping functions. Whereas IDO1 modulates T-cell inflamed states, IDO2 influences B-cell inflamed states critical for autoimmunity²⁰ as well as certain cancers like pancreatic cancer^{23, 24}. IDO2 targeting may pose an additional benefit in mitigating autoimmune side-effects of immune checkpoint therapy based on evidence of a role in autoimmune inflammation^{20, 25}. Lastly, resistance to IDO1 blockade in preclinical models is associated with upregulated Trp catabolism down the kynurenine pathway by TDO or IDO2¹². In the wake of these discoveries, the next logical step would be the development of dual or broad spectrum inhibitors of tryptophan catabolism to target IDO1, IDO2 and TDO.

Although a large number of IDO1 inhibitors have been communicated^{26, 27}, there are significantly fewer TDO^{22, 28-32} and IDO2 inhibitors³³⁻³⁵ described in the literature. To the best of our knowledge, there is only one report of dual inhibition in the literature³¹, although a collection of patents have appeared³⁶⁻³⁹. Our recent report of monoaryl hydroxylamine activity as an

impressive, structurally simple IDO1 inhibitor⁴⁰ prompted us to explore this structural class of compounds further for combinatorial activity against IDO/TDO enzymes. Cognizant of the potential therapeutic benefits that might accrue from joint inhibition of IDO2 and TDO, we therefore screened more broadly for the effects of diaryl hydroxylamines on IDO2 and TDO as well as IDO1, to identify pan or selective inhibitors.

Based on literature defining two major pockets termed A and B in the active site of IDO1^{26, 41-43}. The expansion of our previously reported monoaryl hydroxylamines to diaryl derivatives was conceived initially as an effort to exploit both pockets in IDO1 to achieve more potent and selective inhibition. In addition, IDO1's substrate profile has always suggested greater promiscuity relative to TDO^{44, 45} and the reported flexibility of the enzyme⁴¹ likely contributes to the ability of IDO1 to accommodate a range of structures. We were cognizant of these challenges and opportunities as we explored a new structural derivative of the monoaryl hydroxylamines. Herein we report our results with regards to these studies.


2. Results and Discussion

2.1 Synthesis of diaryl inhibitors.


The synthesis of the diaryl inhibitors followed the pattern of the previously reported monoaryl hydroxylamines⁴⁰ in using the Mitsunobu reaction of an alcohol with N-hydroxyphthalimide to create the critical hydroxylamine functional group. The alcohol precursors of the Mitsunobu reaction were usually synthesized by adding phenyllithium or phenyl Grignard to the appropriate aldehyde (Scheme 1). Details for the synthesis of all alcohol precursors to the Mitsunobu reaction are shown in the Supplementary Data appendix. The

Mitsunobu sequence shown in Scheme 2 illustrates the transformation of the alcohol substrates to O-alkylhydroxylamines.

Scheme 1. Synthesis of Diaryl Alcohols with One Ring Substituted



Scheme 2. Mitsunobu Reaction to Convert Alcohols to O-Alkyl Hydroxylamines



2.2 Enzyme inhibition data analysis.

Analysis of the diaryl compounds with isolated enzyme assays for IDO1, IDO2 and TDO activity allowed a preliminary ranking of the derivatives (Table 1). These results illustrated an array of activity and selectivity in this class of dioxygenase inhibitors. In all cases, compounds were tested as racemic mixtures, so it is possible that one enantiomer is the preferred and more potent stereoisomer. IDO1, which is the primary focus of most therapeutic work, was most potently inhibited by compounds with bromo and chloro substituents on the aromatic rings (compounds **1-7**) with a potency in the range of 1-4 μM . This was also consistent with the results from our studies with the monoaryl hydroxylamines⁴⁰. Methoxy or hydroxy substituted derivatives (**20**, **23**, **25**) were noticeably less potent (23 μM , 85% inhibition and 18% inhibition,


respectively). The preference for bromo and chloro substitution on IDO1 inhibitors has also been found with the most potent compounds that have entered the clinic⁴.



In addition to the potency enhancing effects of halogenated derivatives towards IDO1 inhibition, we found two modifications that often led to IDO1 selective inhibitors: 2-fluoro substitution of one aryl ring (**10**, **12**, **13**, **16**) and diaryl derivatives with a longer chain of atoms between the two aryl rings (**5**, **11**, **17**). In the ortho-fluoro substitution cases, the two most potent examples also have a trifluoromethyl group on the same ring and therefore the highly electron deficient aryl ring may be critical for IDO1 selectivity. With respect to the diaryls with greater distance between the two aryl rings, their selectivity is likely the result of the extended second aryl group better occupying the B pocket of IDO1. Inhibitors that occupy both the A and B pockets of IDO1 often have greater potency^{42, 43}, although, to the best of our knowledge, our discovery is the first to illustrate selectivity from an extended binding inhibitor. This could be critical to the development of more selective inhibitors of the dioxygenase family.




New pan, dual and selective dioxygenase inhibitors were also identified (Fig. 1). For example, compound **3** with the 3,4-dichloro aryl ring substitution, was a pan inhibitor (IDO1/IDO2/TDO potency: 2, 32, 4 μ M, respectively). Several of the chlorinated and fluorinated derivatives demonstrated dual IDO1/TDO inhibition, including **4** (4,4'-dichloro), **6** (2,4-dichloro), **8** (4-chloro), **9** (3-fluoro), **14** (2,3-dichloro), and **15** (4,4'-difluoro). All six had IDO1 and TDO IC₅₀ values in the single digit micromolar range. One dual IDO1/IDO2 inhibitor was identified in the 2-chloro substituted diaryl derivative, compound **19**, which had IC₅₀ values of 18 and 25 μ M for IDO1 and IDO2, respectively. There was one diaryl compound (**26**) tested that was a selective TDO inhibitor (12 μ M). Twelve of the other compounds were IDO1 selective: **1**, **2**, **5**, **7**, **10-13**, **16-18**, and **20**. As noted earlier, seven of these derivatives fit into one of two

categories: (1) 2-fluoro substitution (**10**, **12**, **13**, **16**) or (2) extended distance between the two aromatic rings (**5**, **11**, **17**). Four of the IDO1 selective inhibitors had 3,5-dihalo (**2** and **7**) or 2-position substitution (**18** and **20**). The most potent compound, **1**, fit none of these patterns as it had a 3-bromo substitution, thereby demonstrating the empirical nature of much of this analysis.

Table 1. Enzyme Inhibition Data for Diaryl Hydroxylamines with Ring Substitution^a




Compound no.	Structure ^a	IDO1 (μM or % inhibition) ^b	IDO2 (μM or % inhibition) ^b	TDO (μM or % inhibition) ^b
1	3-bromo	1 μM	77.6%	92.6%
2	3,5-dichloro	2 μM	69.8%	83.4%
3	3,4-dichloro	2 μM	32 μM	4 μM
4	4,4'-dichloro	3 μM	69.3%	2 μM
5		3 μM	84.3%	75.5%
6	2,4-dichloro	4 μM	73%	6 μM
7	3,5-difluoro	4 μM	83%	92.6%
8	4-chloro	5 μM	74.3%	5 μM
9	3-fluoro	5 μM	82%	6 μM
10	2-fluoro-3-trifluoromethyl	6 μM	81.1%	93.2%
11		7 μM	78.1%	93.1%
12	2,4-difluoro	7 μM	46%	90.3%
13	2-fluoro-5-trifluoromethyl	8 μM	73.8%	73.4%
14	2,3-dichloro	8 μM	72.4%	9 μM

15	4,4'-difluoro	9 μ M	73.6%	9 μ M
16	2-fluoro	12 μ M	77.8%	87.2%
17		16 μ M	76.0%	89.9%
18	2-bromo	17 μ M	81.0%	90.4%
19	2-chloro	18 μ M	25 μ M	89.8%
20	2-methoxy	23 μ M	80.0%	80.3%
21		83%	76.5%	93.3%
22		76%	88.6%	43.6%
23	2-methoxy-4-methyl-4'-chloro	85%	73.8%	66%
24	3,5-bis(trifluoromethyl)	56%	53.3%	50.8%
25	4-hydroxy	18.3%	72.3%	48.7%
26	3-trifluoromethyl	18%	36.1%	12 μ M

^a In all structures, n=0 unless otherwise shown.

^bThe inhibition activity of each compound as listed was first tested with 100 μ M inhibitor (except 24 and 25, which were tested with 200 μ M inhibitor), IC₅₀ values were then determined for those exhibiting >95% inhibition activity.

Figure 1. Venn diagram of selectivities seen with diaryl hydroxylamines in enzyme inhibition assay.



2.3 Cell-based data analysis.

The first point that was noticeable in the cell-based IC_{50} data (Table 2) was that almost all inhibitors demonstrated more potent inhibition than in the isolated enzyme assay. This is quite common with IDO1 screens^{46, 47} and seems reasonable to expect for the similarly challenging isolated enzyme assays for TDO and IDO2. In particular, the IDO1 enzyme assay uses a surrogate reduction system (typically methylene blue and ascorbic acid) which is not the native reduction operation, to maintain the IDO1 in its catalytically active ferrous state; for although there is no redox cycling in the catalytic reaction, IDO1 is quite prone to oxidation to the ferric heme in the presence of oxygen. Also, as with the isolated enzyme assays, all compounds were tested as racemic mixtures.

The cell-based and isolated enzyme screens generally demonstrated similar relative potency for IDO1, IDO2 and TDO in most cases, although some differences in selectivity profiles were observed. For example, the same bromo and dichloro substituted derivatives (**1-4**) that were potent IDO1 inhibitors in the isolated enzyme assay were also potent IDO1 inhibitors in the cell-


based assays (0.6-2 μM). However, the cell-based data for these compounds exhibited more significant potency with IDO2 and TDO as well. Indeed, most of the diaryl compounds demonstrated pan inhibition with high nanomolar or low micromolar inhibition of all three tryptophan catabolizing enzymes (Figure 2) . In all these cases, the potency for IDO1 was the strongest, albeit in some examples only marginally so or within experimental error. For comparison and as proof of the significant pan inhibitor potency of the diaryl hydroxylamines, two clinical IDO1 inhibitor candidates, epacadostat (INCB24360) and PF-068400003, were tested and are included in Table 2 and the Venn Diagram Figure 2. Although INCB24360 shows pan inhibition at roughly the same level as many of the more IDO1 selective diaryl inhibitors, the structural simplicity of the diaryl hydroxylamine inhibitors and their ease of synthesis (3 steps versus 14 steps for epacadostat) makes them an important discovery and an exciting new lead compound series.



As with the enzyme assays, the halogenated derivatives (fluoro, chloro and bromo) were the most potent and, within these examples, the dihalogenated versions (**2-4**, **6**, **7**, **12**, **14**, **15**) demonstrated stronger pan inhibition than the monohalogenated analogs (**5**, **8**, **11**, **16**, **18**, **19**), which had at least one inhibition constant above 20 μM . The meta monofluorinated **9** demonstrated IDO1 selective inhibition, along with three ortho monosubstituted derivatives **18-20**, which had roughly five- to ten-fold greater potency with IDO1 (~ 1 μM) than either IDO2 (~ 10 μM) or TDO (>20 μM). The power of ring halogenation was also witnessed in our previous report⁴⁰ on monoaryl O-alkylhydroxylamine derivatives as IDO1 inhibitors.






As with the isolated enzyme assay, the extended binding inhibitor **5** with the greater distance between the two aryl rings demonstrated more than 20-fold selectivity for IDO1 over

IDO2 and TDO. However, the other extended binding inhibitors, **11** and **17**, were less potent and less selective, illustrating that compound **5** has the better distance between the two aryl rings to generate selective and maximum IDO1 inhibition. Interestingly, there were two compounds, **16** and **21**, which showed dual IDO1/TDO inhibitor activity with roughly 10-fold greater potency for IDO1 and TDO (~1-5 μM) over IDO2 (~30-50 μM). Notably, the loss of the second aryl ring, as in compound **22**, resulted in significant attenuation in overall inhibition activity and for TDO in particular. This example serves as an important illustration of the requisite diaryl character in these inhibitors. Surprisingly, the four least potent compounds in the isolated enzyme assay (**23-26**) showed single micromolar potency towards IDO1 in the cell-based assay and retained low micromolar inhibition of IDO2 and TDO. Again, this is likely attributed to differences in the isolated enzyme assay procedure versus the cell-based assay.

Table 2. Inhibition Data (IC_{50} values) for Cell-based Assays of Diaryl Hydroxylamines with Ring Substitution^a



Compound no.	Structure ^a	IDO1 (μM) ^b	IDO2 (μM)	TDO (μM)
Epacadostat (INCB24360)		0.07	18.9	25.2
PF-06840003		0.21	327	378
1	3-bromo	0.590	11.8	7.15
2	3,5-dichloro	0.870	8.66	5.70

3	3,4-dichloro	1.91	19.5	8.11
4	4,4'-dichloro	1.09	12.5	4.53
5		1.43	36.1	123
6	2,4-dichloro	1.99	7.68	4.82
7	3,5-difluoro	0.357	8.75	3.48
8	4-chloro	7.15	27.8	23.7
9	3-fluoro	0.939	9.99	6.21
10	2-fluoro-3-trifluoromethyl	0.933	16.8	5.62
11		6.74	20.5	58.7
12	2,4-difluoro	1.21	18.9	6.37
13	2-fluoro-5-trifluoromethyl	1.09	8.94	9.02
14	2,3-dichloro	1.87	8.95	4.54
15	4,4'-difluoro	1.68	12.1	5.15
16	2-fluoro	1.26	30.5	3.92
17		14.7	19.3	49.7
18	2-bromo	1.46	12.3	22.5
19	2-chloro	2.48	10.7	21.8
20	2-methoxy	1.11	16.5	48.8
21		3.36	49.9	4.41
22		21.0	40.2	2770
23	2-methoxy-4-methyl-4'-chloro	1.76	8.77	19.1
24	3,5-bis(trifluoromethyl)	3.35	14.5	77.4
25	4-hydroxy	2.89	12.6	29.8
26	3-trifluoromethyl	1.73	24.7	13.6

^aIn all structures, n=0 unless otherwise shown.

^bThe IDO1 assay used HeLa cells, the IDO2 assay used mouse Trex cells and the TDO assay used Trex cells. Data is from a single data point except for the most potent compounds, which were done in triplicate and the results averaged.




Figure 2. Venn diagram of selectivities seen with diaryl hydroxylamines in cell-based assay.

Compound associated cytotoxicity could be a possible complicating factor for interpreting the cell-based enzyme inhibition data and a potential concern with regard to safety and tolerability. Therefore, a viability screen with HeLa cells was undertaken which demonstrated roughly $\geq 80\%$ viability up to 100 μM for all compounds except for **1**, **12** and **24** (See Supplementary Data appendix, **Figure S3**). For these three compounds, the cell viability dropped to approximately 60% around 100 μM . The overall lack of cytotoxicity apparent at the effective inhibitory dose range for these compounds suggests that general cytotoxicity is not

likely to be an issue for advancing the diaryl hydroxylamine series. It was clear that the diaryl hydroxylamines, like the monoaryl hydroxylamines, have little to suggest that they would be problematic. Assessment of impact of human serum protein binding indicated a substantial reduction in inhibitory activity for one of the compounds, **6**, while the inhibitory activity of **2** was relatively unaffected (see Supplementary Data appendix, **Figure S4**). This analysis indicates that it should be possible to develop diaryl hydroxylamines inhibitors that are not unduly compromised by serum protein binding.

3. Conclusions

Several important discoveries were made in the studies reported here. First, diaryl hydroxylamines demonstrated strong potency in isolated enzyme assays and were even stronger in cell-based assays. This reaffirms a common pattern for IDO1 inhibition studies and alerts researchers in the field that isolated enzyme studies should be interpreted with caution. This is understandable because the isolated enzyme assay for these Trp catabolizing enzymes is not an accurate replication of the actual cell environment. Second, the value of halogenation (fluoro, chloro and bromo) to potency in all three enzymes is a critical recognition, echoing the most potent IDO1 inhibitors that have entered the clinic. Third, as seen with **5**, extended binding inhibitors do offer selectivity for IDO1 over the two other dioxygenase enzyme targets. Most notably, this study illustrates a rare example of potent pan and IDO1/TDO selective inhibitors. Although IDO1 inhibitors have been developed and reported for over a decade²⁶, the development of pan or variably selective inhibitors is still in its infancy. Indeed, given the recent failure of the IDO1-selective inhibitor epacadostat in the ECHO-301 Phase 3 trial in melanoma, it seems likely that dual or pan inhibitors may be important to the development of effective therapeutic inhibitors of tryptophan catabolism¹¹. The illustration in this report that these

relatively simple inhibitors have significant potency and unique selectivity is an important development in the field that should benefit other researchers. Future studies will seek to further advance these understandings in the creation of more therapeutically relevant structures.

4. Experimental Section

General Synthetic Chemistry Experimental Parameters

All reactants and reagents were commercially available and were used without further purification unless otherwise indicated. Anhydrous CH_2Cl_2 was obtained by distillation from calcium hydride under nitrogen. Anhydrous THF was freshly distilled from Na and benzophenone. All reactions were carried out under an inert atmosphere of argon or nitrogen unless otherwise indicated. Concentrated refers to the removal of solvent with a rotary evaporator at normal water aspirator pressure followed by further evacuation with a direct-drive rotary vane vacuum pump. Thin layer chromatography was performed using silica gel 60 Å pre-coated glass or aluminum backed plates (0.25 mm thickness) with fluorescent indicator, which were cut. Developed TLC plates were visualized with UV light (254 nm), iodine, or ninhydrin. Flash column chromatography was conducted with the indicated solvent system using normal phase silica gel 60 Å, 230-400 mesh. Yields refer to chromatographically and spectroscopically pure (>95%) compounds except as otherwise indicated. Melting points were determined using an open capillary and are uncorrected. ^1H NMR spectra were recorded at 400 MHz. Chemical shifts are reported in δ values (ppm) relative to an internal reference (0.05% v/v) of tetramethylsilane (TMS) for ^1H NMR. Peak splitting patterns in the ^1H NMR are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad. ^{13}C NMR experiments were conducted with the attached proton test (APT) pulse sequence. ^{13}C multiplicities are reported as δ_{u} (up) for methyl and methine, and δ_{d} (down)

for methylene and quaternary carbons. HPLC was conducted on an Agilent 1100 with an Ascentis Express C-18 column (100 x 4.6 mm, 2.7 μ m) and a mobile phase of 80:20 MeCN:H₂O. GC analyses were performed on the free hydroxylamine with an EI-MS detector fitted with a 30 m x 0.25 mm column filled with cross-linked 5% PH ME siloxane (0.25 μ m film thickness); gas pressure 7.63 psi He. Analysis of samples involved heating from 70 to 250°C (10°C/min) and finally holding at 250°C for 7 min. All compounds were found to be >95% purity by elemental analysis or GC as indicated.

General Synthesis of O-Alkyl Hydroxylamines.

To a solution of alcohol (1 mmol) in freshly distilled THF (5 ml) was added triphenylphosphine (1.1 mmol) and N-hydroxylphthalimide (1.1 mmol). After the solution was cooled to 0°C diisopropylazodicarboxylate (1.1 mmol) was added dropwise. The solution was allowed to warm to room temperature over 3 hours. Reaction progress was monitored by TLC (1:1 heptanes:ethyl acetate). Hydrazine monohydrate (1.1 mmol) was then added and the solution was allowed to stir for 30 min. Water was added to dissolve the white precipitate. The aqueous layer was then extracted with ethyl acetate 3 times, washed with brine, and dried over Na₂SO₄. Removal of the solvent under reduced pressure afforded a yellow oil that was purified by flash chromatography (1:1 heptanes/ethyl acetate with 0.1% triethylamine).

HCl salt formation: The O-alkyl hydroxylamine was dissolved in a minimal amount of diethyl ether. HCl in anhydrous diethyl ether (1.0 M, 1 eq) was added slowly. The white precipitate was filtered and washed with diethyl ether and dried under high vacuum.

O-(3-Bromo- α -phenylbenzyl)hydroxylamine hydrochloride (1). Synthesized from 3-bromo- α -phenyl-benzenemethanol according to the general procedure to afford **1** as white crystals in 66% yield. Mp=159-162°C. ¹H NMR (CD₃OD) δ 7.57-7.60 (m, 2H, ArH), 7.33-7.52 (m, 7H, ArH),

6.11 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 132.0, 130.5, 130.0, 129.3, 128.9, 127.3, 126.0, 87.0; δ_{d} 139.8, 136.5, 122.5. Anal. calcd. for $\text{C}_{13}\text{H}_{13}\text{ClBrNO}$ C=49.63, H=4.17, N=4.45. Found: C=49.63%, H=4.48%, N=4.38%.

O-(3,5-Dichloro- α -phenylbenzyl)hydroxylamine hydrochloride (**2**). Synthesized from 3,5-dichloro- α -phenyl-benzenemethanol according to the general procedure to afford **2** as white crystals in 88% yield. Mp= 172-177 °C. ^1H NMR (CD_3OD) δ 7.38-7.44 (m, 4H, ArH), 7.24(d, 2H, ArH, $J=8.6$ Hz), 6.84-6.87 (d, 2H, ArH, $J=6.68$ Hz), 6.01 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 131.7, 131.2, 130.9, 129.5, 127.8, 88.5; δ_{d} 143.6, 138.4, 137.6. Anal. calcd. for $\text{C}_{13}\text{H}_{12}\text{Cl}_2\text{NO}$: C=51.26; H=3.97; N=4.60. Found: C=51.54%, H=3.69%, N=4.57%.

O-(3,4-Dichlorophenylbenzyl)hydroxylamine hydrochloride (**3**). Synthesized from respective alcohol according to the general procedure to afford **3** as white crystals in 67% yield. Mp=155-156°C. ^1H NMR (CD_3OD) δ 7.61 (d, 2H, ArH, $J=8.0$ Hz), δ 7.50-7.44 (m, 4H, ArH), δ 7.36-7.34 (d, 1H, ArH, $J=8.0$ Hz), δ 6.18 (s, 1H, ArCH(OH $_2$)). ^{13}C NMR (CD_3OD) δ_{u} 130.8, 129.4, 129.1, 129.0, 127.2, 126.9, 86.4; δ_{d} 138.0, 136.2, 132.8, 132.6. Anal. calcd. for $\text{C}_{13}\text{H}_{12}\text{Cl}_2\text{NO}$: C=51.26; H=3.97; N=4.60. Found: C=51.26%, H=3.65%, N=4.41%.

O-[Bis(4-chlorophenyl)methyl]-hydroxylamine hydrochloride monohydrate (**4**). Synthesized from bis-4-chlorophenyl methanol according to the general procedure to afford **4** as white crystals in 49% yield. Mp=201-202°C. ^1H NMR (CD_3OD) δ 7.46-7.48 (d, 2H, ArH, $J=8.40$ Hz), 7.39-7.41 (d, 2H, ArH, $J=8.48$ Hz), 6.08 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 128.9, 86.3; δ_{d} 135.6, 135.0. Anal. calcd. for $\text{C}_{13}\text{H}_{14}\text{Cl}_2\text{NO}\cdot 0.5$ HCl C=48.36, H=3.91, N=4.34. Found: C=48.52%, H=3.87%, N=4.19%.

5-(Aminoxy)-5-(3-chlorophenyl)-*N*-phenylpentanamide hydrochloride (**5**). Synthesized from the respective alcohol according to the general procedure with the following modifications: A resin-

bound triphenylphosphine was used and the intermediate N-hydroxy-phthalimide intermediate was purified by column chromatography and then used immediately in the next hydrazinolysis step. The product was obtained as a white solid in 62% yield. Mp=182-184°C. ¹H NMR (d₆-DMSO) δ 10.97 (br s, 3 H, NH₃), 10.05 (s, 1 H, NH-C(=O)), 7.6 (d, 1 H, ArH, J=8.0 Hz), 7.47 (d, 3 H, ArH, J=4.0 Hz), 7.39-7.37 (m, 1 H, ArH), 7.27 (t, 2 H, ArH, J=8.0 Hz), 7.01 (t, 1 H, ArH, J=8.0 Hz), 5.19 (t, 1 H, NO-CH, J=6.4 Hz), 2.37 (t, 2 H, O=CCH₂, J=4.0 Hz), 1.97-1.88 (m, 1 H, CH₂), 1.78-1.60 (m, 2 H, CH₂), 1.58-1.47 (m, 1 H, CH₂). ¹³C NMR (d₆-DMSO) δ_u 131.1, 129.3, 129.1, 127.6, 126.4, 123.4, 119.5, 85.0; δ_d 171.3, 141.0, 139.8, 133.8, 36.1, 34.8, 21.6. GC t_R = 22.528 min.

O-(2,4-Dichlorophenylbenzyl)hydroxylamine hydrochloride (**6**). Synthesized from 2,4-dichlorophenylbenzhydrol according to the general procedure to afford **6** as white crystals in 76% yield. Mp=170-171.5°C. ¹H NMR (CD₃OD) δ 7.56-7.57 (m, 2H, ArH), 7.47-7.51 (m, 6H, ArH) 6.46 (s, 1H, ArCH). ¹³C NMR (CD₃OD) δ_u 129.6, 128.9, 128.8, 127.8, 127.7, 84.0; δ_d 135.4, 135.0, 134.0, 133.7. Anal. calcd. for C₁₃H₁₂Cl₃NO·0.25 HCl: C=49.77, H=3.94, N=4.47. Found: C=49.66%, H =4.17%, N =4.40%.

O-(3,5-Difluoro- α -phenylbenzyl)hydroxylamine hydrochloride (**7**). Synthesized from 3,5-difluoro- α -phenyl benzenemethanol according to the general procedure to afford **7** as white crystals in 89% yield. Mp=177-181°C. ¹H NMR (CD₃OD) δ 7.65-7.68 (m, 3H, ArH) 7.45-7.48 (m, 1H, ArH), 7.36-7.44 (m, 4H, ArH), 6.52 (s, 1H, ArCH). ¹³C NMR (CD₃OD) δ_u 129.5, 128.9, 127.3, 110.0 (q, ²J_{C-F}=19, 8 Hz), 103.9 (t, ²J_{C-F}=25 Hz) 86.4; δ_d 163.3 (dd, ¹J_{C-F}=250 Hz, ³J_{C-F}=13 Hz), 141.7 (d, J_{C-F}=8 Hz), 136.1. GC t_R = 10.764 min.

O-(4-Chloro- α -phenylbenzyl)hydroxylamine hydrochloride (**8**). Synthesized from 4-chloro- α -phenyl-benzenemethanol according to the general procedure to afford **8** as white crystals in 54%

yield. Mp=171-175°C. ^1H NMR (CD_3OD) δ 7.38-7.44 (m, 4H, ArH), 7.24 (d, 2H, ArH, $J=8.6$ Hz), 6.85 (t, 1H, ArH, $J=6.7$ Hz), 6.01 (s, 1H, ArCH₂). ^{13}C NMR (CD_3OD) δ_{u} 129.2, 128.8, 128.4, 127.2, 87.2; δ_{d} 136.6, 136.0, 134.9. Anal. calcd. for C₁₃H₁₃Cl₂NO: C=57.80; H=4.85; N=5.18. Found: C=58.02%, H = 4.58%, N =5.14%.

O-(3-Flouro- α -phenylbenzyl)hydroxylamine hydrochloride (**9**). Synthesized from 3-flouro- α -phenyl-benzenemethanol according to the general procedure to afford **9** as white crystals in 77% yield. Mp=169-170°C. ^1H NMR (CD_3OD) δ 7.43-7.44 (m, 6H, ArH) 7.24-7.26 (m, 1H, ArH), 7.14-7.20 (m, 2H, ArH), 6.15 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 130.6 (d, $^3\text{J}_{\text{C-F}}=8$ Hz), 129.2, 128.8, 127.3, 123.0 (d, $^3\text{J}_{\text{C-F}}=3$ Hz), 115.6 (d, $^2\text{J}_{\text{C-F}}=21$ Hz), 113.8 (d, $^2\text{J}_{\text{C-F}}=23$ Hz), 87.0; δ_{d} 163.0 (d, $^1\text{J}_{\text{C-F}}=245$ Hz), 139.9 (d, $^3\text{J}_{\text{C-F}}=7$ Hz), 136.6. Anal. calcd. for C₁₃H₁₃ClFNO C=61.55; H=5.17; N=5.52. Found: C=61.21%, H = 4.79%, N =5.48%.

O-(2-Fluoro-3-trifluoromethyl- α -phenylbenzyl)hydroxylamine hydrochloride (**10**). Synthesized from 2-fluoro-4-trifluoromethyl)- α -phenyl benzenemethanol according to the general procedure to afford **10** as white crystals in 61% yield. Mp=157-158°C. ^1H NMR (CD_3OD) δ 7.38-7.44 (m, 4H, ArH), 7.24 (d, 2H, ArH, $J=8.6$), 6.85 (t, 1H, ArH, $J=6.7$), 6.01 (s, 1H, ArCH(OH₂)). ^{13}C NMR (CD_3OD) δ_{u} 132.1 (d, $^3\text{J}_{\text{C-F}}=3$ Hz), 129.6, 129.0, 127.9 (m), 127.2, 124.9 (d, $^3\text{J}_{\text{C-F}}=5$ Hz), 81.1 (d, $^3\text{J}_{\text{C-F}}=3$ Hz); δ_{d} 157.2 (d, $^1\text{J}_{\text{C-F}}=250$ Hz), 135.2, 126.7 (t, $^2\text{J}_{\text{C-F}}=13$ Hz), 122.5 (d, $^1\text{J}_{\text{C-F}}=270$ Hz), 118.4 (q, $^2\text{J}_{\text{C-F}}=33, 12$ Hz). Anal. calcd. for C₁₄H₁₂ClF₄NO: C=52.27, H=3.76, N=4.35. Found: C=52.39%, H =3.49%, N =4.29%.

O-(3-(3-chlorophenyl)-1-phenylpropyl)hydroxylamine hydrochloride (**11**) Synthesized from the respective alcohol according to the general procedure to afford **11**. Mp=140.5-141.5°C. ^1H NMR (CD_3OD) δ 7.44-7.54 (m, 5 H, ArH), 7.28 (t, 1 H, ArH, $J=8.0$ Hz), 7.22 (s, 2 H, ArH), 7.13 (d, 1 H, ArH, $J=8.0$ Hz), 4.98 (t, 1 H, ArCH(OH₂), $J=6.9$ Hz), 2.59-2.76 (m, 2 H, ArCH₂), 2.27-2.37

(m, 1 H, ArCH₂CH₂), 2.05-2.15 (m, 1 H, ArCH₂CH₂). ¹³C NMR (CD₃OD) δ_u 129.7, 129.6, 129.0, 128.1, 127.2, 126.5, 126.0, 86.5; δ_d 143.0, 136.6, 134.0, 36.6, 30.8. GC t_R=14.656 min.

O-(2,4-Difluorophenylbenzyl)hydroxylamine hydrochloride (**12**). Synthesized from respective alcohol according to the general procedure to afford **12** as white crystals in 62% yield. Mp=167-168°C. ¹H NMR (CD₃OD) δ 7.46-7.43 (overlapping signal, 5H, ArH), δ 7.11-7.05 (overlapping signal, 2H, ArH), δ 6.38 (s, 2H, ArCH(OH₂)). ¹³C NMR (CD₃OD) δ_u 129.6 (d, ³J_{C-F}=4 Hz), 129.5 (d, ³J_{C-F}=4 Hz), 129.3, 128.8, 127.1, 111.7 (q, ²J_{C-F}=22 Hz, ³J_{C-F}=4 Hz), 104.0 (t, ²J_{C-F}=25 Hz), 81.4 (d, ³J_{C-F}=3 Hz); δ_d 163.6 (d, ¹J_{C-F}=249 Hz, ³J_{C-F}=13 Hz), 160.8 (d, ¹J_{C-F}=249 Hz, ³J_{C-F}=12 Hz), 135.6, 120.9 (q, ²J_{C-F}=13 Hz, ⁴J_{C-F}=4 Hz). GC t_R = 10.835 min.

O-((2-Fluoro-5-trifluoromethyl-*α*-phenylbenzyl)hydroxylamine hydrochloride (**13**). Synthesized from the respective alcohol according to the general procedure to afford **13** as white crystals in 91% yield. Mp=157-158.5°C. ¹H NMR (CD₃OD) δ 7.78-7.82 (m, 2H, ArH), 7.40-7.51(m, 6H, ArH),6.45(1H, ArCH(OH₂)). ¹³C NMR (CD₃OD) δ_u 129.6, 129.0, 128.5, 127.3, 125.0 (t, ³J_{C-F}=4 Hz), 116.9 (d, ²J_{C-F}=23 Hz), 81.3; δ_d 162.1 (d, ¹J_{C-F}=254 Hz), 135.1, 129.6, 126.3 (d, ²J_{C-F}=14 Hz). GC t_R = 10.494 min.

O-(2,3-Dichloro-*α*-phenylbenzyl)hydroxylamine hydrochloride (**14**). Synthesized from 2,3-dichloro-*α*-phenyl-benzenemethanol according to the general procedure to afford **14** as white crystals in 63%yield. Mp=170-175°C. ¹H NMR (CD₃OD) δ 7.64 (dd, 1H, ArH, J=2.1, 8.0 Hz), 7.60 (dd, 1H, ArH, J=1.4 Hz, 7.8 Hz), 7.42-7.80 (m, 6H, ArH), 6.53 (s,1H, ArCH). ¹³C NMR (CD₃OD) δ_u 130.8, 129.5, 128.8, 128.2, 128.0, 125.9, 84.8; δ_d 137.2, 135.0, 133.6, 131.1. Anal. calcd. for C₁₃H₁₂Cl₃NO: C=51.26; H=3.97; N=4.60. Found: C=51.27%, H = 3.90%, N =4.52%.

O-[Bis(4-fluorophenyl)methyl]-hydroxylamine hydrochloride (**15**). Synthesized from bis-4-fluorophenyl methanol according to the general procedure to afford **15** as white crystals in 58%

yield. Mp=164-165.5°C. ^1H NMR (CD_3OD) δ 7.44-7.46 (m, 4H, ArH), 7.18-7.23 (m, 4H, ArH), 6.12 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 129.5 (d, $^3\text{J}_{\text{C-F}}=8$ Hz), 115.5 (d, $^2\text{J}_{\text{C-F}}=22$ Hz), 86.4; δ_{d} 163.2 (d, $^1\text{J}_{\text{C-F}}=246$ Hz), 133.0 (d, $^4\text{J}_{\text{C-F}}=3$ Hz). Anal. calcd. for $\text{C}_{13}\text{H}_{12}\text{ClF}_2\text{NO}$ C=57.47, H=4.45; N=5.16. Found: C=57.29%, H = 4.51%, N =5.16%.

O-(2-Fluoro- α -phenylbenzyl)hydroxylamine hydrochloride (**16**). Synthesized from 2-fluoro- α -phenyl benzenemethanol according to the general procedure to afford **16** as white crystals in 85% yield. Mp=184-185°C. ^1H NMR (CD_3OD) δ 7.42-7.50 (m, 7H, ArH), 7.27-7.31 (t, 1H, ArH, $J=6.60$ Hz), 7.18-7.23 (t, 1H, ArH, $J=8.64$ Hz), 6.44 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 131.0 (d, $^3\text{J}_{\text{C-F}}=8$ Hz), 129.2, 128.8, 127.8 (d, $^4\text{J}_{\text{C-F}}=3$ Hz), 127.2, 124.6 (d, $^3\text{J}_{\text{C-F}}=4$ Hz), 115.6 (d, $^2\text{J}_{\text{C-F}}=22$ Hz), 81.8 (d, $^3\text{J}_{\text{C-F}}=4$ Hz); δ_{d} 160.4 (d, $^1\text{J}_{\text{C-F}}=246$ Hz), 135.9, 124.5 (d, $^2\text{J}_{\text{C-F}}=13$ Hz). Anal. Calcd. for $\text{C}_{13}\text{H}_{13}\text{ClFNO}$ C=61.83; H=5.17; N=5.52. Found: C=61.83%, H = 4.89%, N =5.48%.

O-(1,3-diphenylpropyl)hydroxylamine hydrochloride (**17**). Synthesized from 1,3-diphenylpropan-1-ol according to the general procedure to afford **17** in 40% yield. Mp=156-159°C. ^1H NMR (CD_3OD) δ 7.45-7.54 (m, 5 H, ArH), 7.30 (t, 2 H, ArH, $J=7.9$ Hz), 7.20 (t, 2 H, ArH, $J=6.2$ Hz), 4.97 (t, 1 H, ArCH(OH₂), $J=6.9$ Hz), 2.60-2.74 (m, 2 H, ArCH₂), 2.28-2.37 (m, 1 H, ArCH₂CH₂), 2.05-2.14 (m, 1 H, ArCH₂CH₂). ^{13}C NMR (CD_3OD) δ_{u} 129.5, 129.0, 128.2, 128.0, 127.2, 126.8, 125.9, 86.9; δ_{d} 140.5, 136.8, 37.0, 31.1. GC $t_{\text{R}}=12.784$ min.

O-(2-Bromo- α -phenylbenzyl)hydroxylamine hydrochloride (**18**). Synthesized from 2-bromo- α -phenyl-benzenemethanol according to the general procedure to afford **18** as white crystals in 34% yield. Mp=166-167°C. ^1H NMR (CD_3OD) δ 7.71 (dd, 1H, ArH, $J=8.0, 1.6$ Hz) 7.61 (dd, 1H, ArH, $J=8.0, 1.6$ Hz), 7.53 (dt, 1H, ArH, $J=8.0, 1.6$ Hz), 7.40-7.48 (m, 5H, ArH), 7.36 (dt, 1H, $J=8.0, 1.6$ Hz), 6.47 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_{u} 135.4, 130.6, 129.3, 129.0, 128.7, 128.0,

127.9, 127.2, 86.6; δ_d 136.2, 135.4, 123.1. Anal. calcd. for $C_{13}H_{13}ClBrNO$: C=49.63; H=4.17; N=4.45. Found: C=49.78%, H =4.38%, N =4.63%.

O-(2-Chloro- α -phenylbenzyl)-hydroxylamine hydrochloride (**19**). Synthesized from 3-chloro- α -phenyl-benzenepropanol according to the general procedure to afford **19** as white crystals in 84% yield. Mp=169-174°C. 1H NMR (CD_3OD) δ 7.50 (d, 1H, ArH, J=4.0 Hz), 7.41-7.48 (m, 8H, ArH), 6.51 (s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_u 130.3, 129.9, 129.3, 128.9, 128.7, 127.9, 127.6, 127.5, 84.5; δ_d 135.5, 134.7, 133.2. GC t_R = 13.022 min.

O-(2-Methoxy- α -phenylbenzyl)hydroxylamine hydrochloride (**20**). Synthesized from 2-methoxy- α -phenyl-benzenemethanol according to the general procedure to afford **20** as white crystals in 89% yield. Mp=134-134.5°C. 1H NMR (CD_3OD) δ 7.35-7.46 (m, 6H, ArH), 6.98-7.01 (m, 3H, ArH), 6.08 (s, 1H, ArCH), 3.81 (s, 3H, ArOCH₃). ^{13}C NMR (CD_3OD) δ_u 129.9, 129.0, 128.6, 127.2, 119.3, 114.2, 112.9, 87.8, 54.4; δ_d 160.2, 138.4, 137.0. Anal. calcd. for $C_{14}H_{16}ClNO_2$: C=63.28, H=6.07, N=5.27. Found: C=63.44%, H = 6.23%, N =5.31%.

O-(phenyl(thiophen-3-yl)methyl)hydroxylamine hydrochloride (**21**). Synthesized from 2-methoxy- α -phenyl-benzenemethanol according to the general procedure to afford **21** as white crystals in 61% yield. Mp=138-139.5°C. 1H NMR (CD_3OD) δ 7.41-7.53 (m, 7 H, ArH), 7.14 (dd, 1 H, ArH, J=5.0, 1.0 Hz), 6.27 (s, 1 H, ArCH(OH₂)). ^{13}C NMR (CD_3OD) δ_u 129.3, 128.7, 128.6, 127.2, 127.0, 126.1, 125.2, 84.2; δ_d 138.1, 136.8. GC t_R =10.857 min.

O-(cyclohexyl(phenyl)methyl)hydroxylamine hydrochloride (**22**). Synthesized from cyclohexyl(phenyl)methanol according to the general procedure to afford **22** in 87% yield. Mp=193-196.5°C. 1H NMR (CD_3OD) δ 7.38-7.52 (m, 5 H, ArH), 4.70 (d, 1 H, ArCH(OH₂), J=8.2 Hz), 2.14 (d, 1 H, CHCHONH₂, J=6.4 Hz), 1.76-1.85 (m, 2 H, CH₂), 1.65-1.68 (m, 2 H,

CH_2), 1.12-1.37 (m, 5 H, CH_2), 0.9-1.03 (m, 1 H, CH_2). ^{13}C NMR (CD_3OD) δ_u 129.3, 128.8, 127.6, 91.7, 42.7 δ_d 135.9, 29.2, 28.5, 25.8, 25.4, 25.2. GC t_R = 10.232 min.

O-[4-Chloro- α -(2'-methyl,4'-methoxyphenyl)benzenemethyl]hydroxylamine hydrochloride (**23**). Synthesized from the respective alcohol according to the general procedure to afford **23** as white crystals in 72% yield. Mp=139.5-140.5°C. 1H NMR (CD_3OD) δ 7.36-7.43 (m, 4H, ArH), 7.19-7.21 (d, 1H, ArH J =7.76 Hz), 6.88-6.93 (m, 2H, ArH), 6.43(s, 1H, ArCHONH₂), 3.87 (s, 3H, ArOCH₃), 2.39 (s, 3H, ArCH₃). ^{13}C NMR (CD_3OD) δ_u 129.2, 128.5, 126.7, 121.3, 111.8, 81.6, 54.7, 20.3; δ_d 157.3, 141.2, 136.0, 134.4, 121.6. Anal. calcd. for C₁₅H₁₇Cl₂NO₂: C=57.34, H=5.45, N=4.46. Found: C=57.60%, H = 5.52%, N =4.36%.

O-(3,5-Bis-trifluoromethyl- α -phenyl-benzyl)hydroxylamine hydrochloride (**24**). Synthesized from 3,5-bis-trifluoromethyl- α -phenyl benzenemethanol according to the general procedure to afford **24** as white crystals in 88% yield. Mp=158-160°C. 1H NMR (CD_3OD) δ 7.90 (m, 3H, ArH), 7.38-7.56 (m, 5H, ArH), 6.31(s, 1H, ArCH). ^{13}C NMR (CD_3OD) δ_u 129.8, 129.2, 127.5, 122.5 (m), 86.0; δ_d 141.0, 135.7, 132.0 (q, $^2J_{C-F}$ =33 Hz), 123.2 (q, $^1J_{C-F}$ =270 Hz). Anal. calcd. for C₁₅H₁₂ClF₆NO: C= 48.47, H=3.25, 3.77. Found: C=48.90%, H =2.98%, N =3.76%.

O-(4-Hydroxy- α -phenyl)-benzyl hydroxylamine hydrochloride (**25**) Synthesized from the 4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]- α -phenyl-benzenemethanol (**25s**) according to the general procedure to afford *O*-[4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]- α -phenyl-benzyl]hydroxylamine. To a solution of the protected phenol (0.3-3.5mmol) in anhydrous tetrahydrofuran (5-25 mL) was added tetrabutylammonium fluoride (1 M, 1.0 equiv per TBDMS), and the pale yellow solution was stirred for 45 min. The mixture was poured into water and extracted with ethyl acetate. Removal of the solvent in vacuo from the organic phase afforded a tan oil that was subjected to gravity column chromatography (9:1 hexane/ethyl acetate). Formation

of the HCl salt followed the general procedure to afford **25** as white crystals in 57% yield. Mp=168.5-169.5°C. ¹H NMR (CD₃OD) δ 7.38-7.46 (m, 5H, ArH), 7.24 (d, 2H, ArH, J=8.6 Hz), 6.86 (d, 2H, ArH, J=8.6 Hz), 6.01 (s, 1H, ArCH). ¹³C NMR (CD₃OD) δ_u 129.8, 128.8, 127.7, 115.6, 69.1; δ_d 158.5, 134.1, 123.9. Anal. calcd. for C₁₃H₁₄ClNO₂·H₂O: C=57.89; H=5.98; N=5.19. Found: C=58.03% H=6.01% N= 5.20% .

O-(3-Trifluoromethyl-*α*-phenylbenzyl)hydroxylamine hydrochloride (**26**). Synthesized from phenyl(3-(trifluoromethyl)phenyl)methanol according to the general procedure to afford **26** as white crystals in 77%yield. Mp=199-199.5°C. ¹H NMR (CD₃OD) δ 7.61 (d, 1H, ArH, J=2.3 Hz), 7.58 (s, 1H, ArH), 7.50 (dd, 1H, ArH, J=8.6, 2.2 Hz), 6.47 (s, 1H, ArCH). ¹³C NMR (CD₃OD) δ_u 132.8, 129.6, 129.3, 128.8, 128.7, 127.6, 126.2 (q, ³J_{C-F}=6 Hz), 83.4; δ_d 136.1, 135.0, 128.3 (d, ²J_{C-F}=30 Hz), 124.2 (q, ¹J_{C-F}=272 Hz). Anal. calcd. for C₁₄H₁₃ClF₃NO: C=55.37; H=4.31; N=4.61. Found: C=55.52%, H = 4.58%, N =5.04%.

Enzyme-based IDO1, IDO2 and TDO inhibition assays. The steady-state activity of each enzyme was measured in the absence or presence of an inhibitor at 20 °C with a protocol reported previously^{48, 49} (with small modifications). For IDO1, each reaction was initiated by mixing 50 μM L-tryptophan with 100 nM enzyme in 50 mM Tris buffer (pH 7.4) that contained 200 nM catalase, 12 μM methylene blue, 20 mM ascorbate and 100 μM inhibitor (unless otherwise indicated). The same protocol was used for IDO2 except that 4 mM L-tryptophan and 1 μM enzyme were used; in addition pyocyanin (39 μM) instead of methylene blue was used as an electron mediator. For TDO, the experiment was initiated by mixing 100 μM L-tryptophan with 250 nM enzyme in 50 mM Tris buffer (pH 7.4) that contained 100 μM ascorbate and 100 μM inhibitor (unless otherwise indicated). The inhibitor stocks were prepared in dimethyl sulfoxide

(DMSO), the final DMSO concentration for all reactions was kept at 3.5% (v/v). The initial linear velocities of the reactions, v , were obtained by monitoring the formation of the product N-formyl kynurenine at 321 nm ($\epsilon = 3750 \text{ M}^{-1}\text{cm}^{-1}$) as a function of time with a UV2400 spectrophotometer (Shimadzu Scientific Instruments, Inc.) with a spectral slit width of 2 nm. The % inhibition for each inhibitor was calculated based on $(1-v/v_0) \times 100$, where v_0 was obtained in the absence of any inhibitor. For each inhibitor that exhibited $\geq 95\%$ inhibition activity for IDO1 or TDO, or $\geq 85\%$ inhibition activity for IDO2, the IC_{50} value was determined by measuring the inhibition activity as a function of inhibitor concentration. It is noted that the threshold for IDO2 was set lower (85%) for the initial screening due to the generally lower inhibition activity of the inhibitors. All the data were analyzed with Origin 6.1 software (Microcal Software, Inc., MA).

Cell-based IDO1, IDO2 and TDO inhibition assays. Compounds were evaluated for inhibitory activity against human *IDO1* expressed endogenously in HeLa cells and human *TDO* and mouse *IDO2* expressed exogenously in T-Rex cells. HeLa cells were seeded in a 96 well plate at a density of 10,000 cells per well in 100 μL DMEM + 10% fetal bovine serum + 1% penicillin-streptomycin with L-tryptophan being adjusted to 100 μM and *IDO1* expression was induced by the addition of $\text{IFN}\gamma$ to a final concentration of 100 ng/mL. T-Rex cells containing a *tet*-regulated human *TDO* were seeded in a 96-well plate at a density of 10,000 cells per well in 100 μL of DMEM + 10% FBS + 1% penicillin-streptomycin with L-tryptophan adjusted to 100 μM and *TDO* expression was induced by the addition of 100 μL of media containing 2 ng/mL doxycycline with adjusted L-tryptophan. T-Rex cells containing a *tet*-regulated mouse *IDO2* cDNA were seeded in a 96-well plate at a density of 10,000 cells per well in 100 μL of DMEM + 10% FBS + 1% penicillin-streptomycin and *IDO2* expression was induced by the addition of 100

μL of media containing 2 ng/mL doxycycline + 8 mM 5-aminolevulinic acid + 20 μM hemin + 4 mM L-tryptophan. The IDO1 and TDO induction was allowed to proceed for 24 hours, the IDO2 was induced for 48 hours. After induction, the media was discarded, the wells rinsed once, and serial dilutions of compound in 200 μL of appropriate media with the final concentration of tryptophan adjusted to 100 μM for IDO1 and TDO and to 2mM for IDO2. Following incubation at 37 °C for an additional 20 hrs, the assay was stopped by the addition of 50 μL of 50% (w/v) TCA to each well, and the cells were fixed by incubating for 1 hr at 4 °C.

Assessment of IDO1, IDO2 and TDO activity

Compound IC_{50} values were assessed from single point dilution series with the most potent compounds subsequently retested two or more times and the results reported as averages. Following the TCA fixation step, the supernatants were transferred to a round-bottomed 96-well plate and incubated at 65 °C for 15 min. The plates were then centrifuged at $1250 \times g$ for 10 min, and 100 μL of clarified supernatant was transferred to a new flat-bottomed 96-well plate and mixed at equal volume with 2% (w/v) p-dimethylaminobenzaldehyde in acetic acid. The yellow reaction was measured at 490 nm using a Synergy HT microtiter plate reader (Bio-Tek, Winooski, VT). Graphs of inhibition curves with IC_{50} values were generated using Prism v.5.0 (GraphPad Software, Inc.).

Supplementary Data

Full experimental details for the synthesis of alcohols that were not commercially available are described. Copies of ^1H and ^{13}C NMR spectra for all tested hydroxylamine compounds are also available. Raw IC_{50} data for top inhibitors in the enzyme and cell-based inhibition assays are

shown. Toxicity screen with HeLa cells for diaryl hydroxylamines, epacadostat and PF-0684003 are available. In addition, an assay assessing the impact of human serum protein binding on the apparent IC50 values is also shown. This material is available at ...

Acknowledgements

Financial support for this work was provided by NIH grants R01 CA109542 (GCP, AJM and WPM) and R01 GM086482 (SRY). AJM and GCP acknowledge additional support from the Lankenau Medical Center Foundation and Main Line Health. GCP holds the Havens Chair for Biomedical Research at the Lankenau Institute for Medical Research. WPM acknowledges additional support from NIH grant GM087291 and Bryn Mawr College. A generous award (CHE-0958996) from the National Science Foundation enabling acquisition of the 400 MHz NMR spectrometer used in these studies is gratefully acknowledged

Conflict of Interest Statement

AJM, WPM and GCP declare interests as inventors of IDO technology licensed to New Link Genetics Corporation, a biopharmaceutical company involved in the clinical development of IDO inhibitors, as described in U.S. Patents Nos. 7705022, 7714139, 8008281, 8058416, 8383613, 8389568, 8436151, 8476454 and 8586636. WPM and GCP are also former scientific advisors and GCP a former grants recipient of New Link Genetics. GCP is currently a scientific advisor for Kyn Therapeutics, which is developing IDO/TDO/AhR small molecule antagonists for cancer treatment. AJM is a scientific advisor and grant recipient of I-O Biotech AG, which is developing IDO vaccines for cancer treatment.

References

1. Ball HJ, Jusof FF, Bakmiwewa SM, Hunt NH, Yuasa HJ. Tryptophan-Catabolizing Enzymes – Party of Three. *Frontiers in Immunology*. 2014;5: 485.
2. Badawy AAB. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. *International Journal of Tryptophan Research : IJTR*. 2017;10: 1178646917691938.
3. van Baren N, Van den Eynde BJ. Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan. *Cancer Immunol Res*. 2015;3(9): 978-985.
4. G.C. Prendergast, W.J. Malachowski, J. DuHadaway and A.J. Muller, Discovery of Idol inhibitors: from bench to bedside, *Cancer Res*. 2017, 77(24), 6795-6811.
5. Prendergast GC, Malachowski WJ, Mondal A, Scherle P, Muller AJ. Chapter Four - Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. In: Galluzzi L, ed. *International Review of Cell and Molecular Biology*. Vol 336. Academic Press; 2018:175-203.
6. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. *Nat Med*. 2005;11.
7. Li M, Bolduc AR, Hoda MN, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. *Journal for ImmunoTherapy of Cancer*. 2014;2(1): 21.
8. Monjazez AM, Kent MS, Grossenbacher SK, et al. Blocking Indoleamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. *Clin Cancer Res*. 2016;22(17): 4328-4340.
9. Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. *J Exp Med*. 2013;210(7): 1389-1402.
10. Long GV, Dummer R, Hamid O, et al. Epcadostat (E) Plus Pembrolizumab (P) Versus Pembrolizumab Alone in Patients (pts) with Unresectable or Metastatic Melanoma: Results of the Phase 3 ECHO-301/KEYNOTE-252 Study. *2018 American Society of Clinical Oncology Annual Meeting*. 36 (suppl; abstract 108). Chicago, IL: American Society of Clinical Oncology; 2018.
11. A.J. Muller, M. Manfredi, Y. Zakharia and G.C. Prendergast, Ido inhibitors for cancer treatment: lessons from ECHO-301 (invited review), *Semin. Immunopathol*. 2018, <https://doi.org/10.1007/s00281-018-0702-0>.
12. Smith C, Chang MY, Parker KH, et al. IDO Is a nodal pathogenic driver of lung cancer and metastasis development. *Cancer Discov*. 2012;2(8): 722-735.
13. Mondal A, Smith C, DuHadaway JB, et al. IDO1 is an Integral Mediator of Inflammatory Neovascularization. *EBioMedicine*. 2016;14: 74-82.
14. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. *Nature*. 2011;478(7368): 197-203.
15. Puccetti P, Fallarino F, Italiano A, et al. Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers. *PLoS One*. 2015;10(4): e0122046.

16. Ochs K, Ott M, Rauschenbach KJ, et al. Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4. *J. Neurochem.* 2015, 136(6),1142-1154.
17. D'Amato NC, Rogers TJ, Gordon MA, et al. A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. *Cancer Res.* 2015;75(21): 4651-4664.
18. Witkiewicz AK, Costantino CL, Metz R, et al. Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. *J Am Coll Surg.* 2009;208(5): 781-787; discussion 787-789.
19. Metz R, Smith C, Duhadaway JB, et al. IDO2 is critical for IDO1-mediated T cell regulation and exerts a non-redundant function in inflammation. *Int Immunol.* 2014;26: 357-367.
20. Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L. IDO2 in Immunomodulation and Autoimmune Disease. *Front Immunol.* 2014;5: 585.
21. Peek RM, Mohla S, DuBois RN. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a National Cancer Institute-sponsored meeting. *Cancer Res.* 2005;65: 8583-8586.
22. Pilotte L, Larrieu P, Stroobant V, et al. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. *Proc Natl Acad Sci U S A.* 2012;109(7): 2497-2502.
23. Gunderson AJ, Coussens LM. B cells and their mediators as targets for therapy in solid tumors. *Exp Cell Res.* 2013;319(11): 1644-1649.
24. Affara NI, Ruffell B, Medler TR, et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. *Cancer Cell.* 2014;25(6): 809-821.
25. Merlo LM, DuHadaway JB, Grabler S, Prendergast GC, Muller AJ, Mandik-Nayak L. IDO2 Modulates T Cell-Dependent Autoimmune Responses through a B Cell-Intrinsic Mechanism. *J Immunol.* 2016;196(11): 4487-4497.
26. Rohrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O. Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. *J Med Chem.* 2015;58(24): 9421-9437.
27. Qian S, Zhang M, Chen Q, He Y, Wang W, Wang Z. IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery. *RSC Advances.* 2016;6(9): 7575-7581.
28. Wu J-S, Lin S-Y, Liao F-Y, et al. Identification of Substituted Naphthotriazoles as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening. *Journal of Medicinal Chemistry.* 2015;58(19): 7807-7819.
29. Pantouris G, Loudon-Griffiths J, Mowat CG. Insights into the mechanism of inhibition of tryptophan 2,3-dioxygenase by isatin derivatives. *Journal of Enzyme Inhibition and Medicinal Chemistry.* 2016;31(sup1): 70-78.
30. Salter M, Hazelwood R, Pogson CI, Iyer R, Madge DJ. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat. *Biochemical Pharmacology.* 1995;49(10): 1435-1442.
31. Pantouris G, Mowat CG. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase. *Biochemical and Biophysical Research Communications.* 2014;443(1): 28-31.
32. Dolušić E, Larrieu P, Moineaux L, et al. Tryptophan 2,3-Dioxygenase (TDO) Inhibitors. 3-(2-(Pyridyl)ethenyl)indoles as Potential Anticancer Immunomodulators. *Journal of Medicinal Chemistry.* 2011;54(15): 5320-5334.

33. Bakmiwewa SM, Fatokun AA, Tran A, Payne RJ, Hunt NH, Ball HJ. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2. *Bioorganic & Medicinal Chemistry Letters*. 2012;22(24): 7641-7646.
34. Li J, Li Y, Yang D, et al. Establishment of a human indoleamine 2, 3-dioxygenase 2 (hIDO2) bioassay system and discovery of tryptanthrin derivatives as potent hIDO2 inhibitors. *European Journal of Medicinal Chemistry*. 2016;123: 171-179.
35. Röhrig UF, Majjigapu SR, Caldelari D, et al. 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2). *Bioorganic & Medicinal Chemistry Letters*. 2016;26(17): 4330-4333.
36. Cowley P, Wise A. *Pharmaceutical Compounds*.
37. Wang Z, Guo W, Zhu J, Hu X. Preparation of highly-efficient IDO/TDO dual inhibitor with nitrogen-containing heterocyclic helical structure.
38. Wang H, Guo Y, Ren B, Wang Z, Zhang G, Zhou C. Preparation of 5 or 8-substituted imidazo[1,5-a]pyridines as selective inhibitors of indoleamine and/ortryptophan 2,3-dioxygenases.
39. Bingham M, Armitage SE, Pesnot T. Preparation of imidazo-pyrrolo-pyridinyl derivatives as IDO and TDO inhibitors for the treatment of IDO -
and TDO - mediated diseases.
40. Malachowski WP, Winters M, DuHadaway JB, et al. O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. *Eur J Med Chem*. 2016;108: 564-576.
41. Sugimoto H, Oda S-i, Otsuki T, Hino T, Yoshida T, Shiro Y. Crystal structure of human indoleamine 2,3-dioxygenase: Catalytic mechanism of O₂ incorporation by a heme-containing dioxygenase. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(8): 2611-2616.
42. A. Lewis-Ballester, K.N. Pham, D. Batabyal, et al., Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1, *Nat. Commun*. 2017, 8(1), 1693.
43. Tojo S, Kohno T, Tanaka T, et al. Crystal Structures and Structure–Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. *ACS Medicinal Chemistry Letters*. 2014;5(10): 1119-1123.
44. Chauhan N, Basran J, Rafice Sara A, et al. How is the distal pocket of a heme protein optimized for binding of tryptophan? *The FEBS Journal*. 2012;279(24): 4501-4509.
45. Forouhar F, Anderson JLR, Mowat CG, et al. Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase. *Proceedings of the National Academy of Sciences*. 2007;104(2): 473.
46. Yue EW, Douty B, Wayland B, et al. Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model. *Journal of Medicinal Chemistry*. 2009;52(23): 7364-7367.
47. Yang S, Li X, Hu F, et al. Discovery of Tryptanthrin Derivatives as Potent Inhibitors of Indoleamine 2,3-Dioxygenase with Therapeutic Activity in Lewis Lung Cancer (LLC) Tumor-Bearing Mice. *Journal of Medicinal Chemistry*. 2013;56(21): 8321-8331.
48. Batabyal D, Yeh SR. Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase. *Journal of the American Chemical Society*. 2007;129(50): 15690-15701.
49. Lu C, Lin Y, Yeh SR. Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase. *J Am Chem Soc*. 2009;131(36): 12866-12867.

